Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial

  12H group
(n = 19)
24H group
(n = 20)
p value
Age, month 25 [2–75] 32 [7–118] 0.196
Men 11 (57.9) 11 (55.0) 1.00
Days of illness at enrollment 5 [4–7] 5 [4–6] 0.915
Risk score 4 [0–7] 1 [0–6] 0.022
Laboratory data
 White blood cell count, 109/L 12.4 ± 3.4 12.4 ± 4.0 0.993
 Neutrophils, % 71.2 ± 13.3 67.2 ± 15.6 0.403
 Platelet count, 1010/L 31.1 ± 7.3 36.2 ± 9.3 0.067
 Albumin, g/L 3.3 ± 0.4 3.5 ± 0.4 0.111
 Creatinine, mg/dL 0.27 ± 0.06 0.27 ± 0.07 0.664
 Aspartate aminotransferase, U/L 99 ± 159 38 ± 21 0.092
 Sodium, mEq/L 133 ± 3 137 ± 3 < 0.01
 C-reactive protein, mg/dL 7.3 ± 3.9 6.4 ± 5.9 0.564
 IgG, mg/dL 624 ± 155 754 ± 167 0.021
  1. Data are median [range], number (percentage), or mean ± SD
  2. IVIG indicates intravenous immunoglobulin
  3. IgG indicates immunoglobulin G
  4. 12H indicates 12 h
  5. 24H indicates 24 h